The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

For example, a project generating over 100 new jobs and stimulating local growth in an economically disadvantaged area might ...

The alliance brings together Cellular Origins, a company focusing on applying robotics and other forms of automation to CGT ...

By 2023, the tone had shifted. Venture capital cooled. According to CB Insights, funding for AI drug discovery start-ups ...

It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

The US healthcare system continues to burden patients with complexity, fragmentation, and out-of-pocket costs they weren't prepared to shoulder.

South Korean electronics giant Samsung has continued a push into the health category with an agreement to buy Xealth, a ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...